Home ›
Leukemia Trials ›
NCT06827899
Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML
A multicenter, prospective, single-arm clinical study of veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) in the treatment of elderly untreated acute myeloid leukemia (AML)
Trial Details
NCT ID NCT06827899
Phase PHASE2
Sponsor The First Affiliated Hospital of Xiamen University
Status RECRUITING
Cancer Type Leukemia
Interventions veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG)
Locations (sample) Xiamen, Fujian, China|24.47979,118.08187
Key Eligibility Criteria
Histologically confirmed acute myeloid leukemia (non-M3). Have not received treatment before and cannot accept standard cytarabine and anthracyclin… Age \>= 60 years old, male or female, expected survival time greater than 3 months; Estimated creatinine clearance \>= 30 mL/min; AST and ALT \<= 3.0 x ULN (unless considered due to leukemic organ involvement). Bilirubin \<= 1.5 x ULN (unless considered due to leukemic organ i…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →